MX340772B - Medios y metodos para fabricar neurotoxina altamente pura. - Google Patents

Medios y metodos para fabricar neurotoxina altamente pura.

Info

Publication number
MX340772B
MX340772B MX2011008759A MX2011008759A MX340772B MX 340772 B MX340772 B MX 340772B MX 2011008759 A MX2011008759 A MX 2011008759A MX 2011008759 A MX2011008759 A MX 2011008759A MX 340772 B MX340772 B MX 340772B
Authority
MX
Mexico
Prior art keywords
unprocessed
relates
processed neurotoxin
present
methods
Prior art date
Application number
MX2011008759A
Other languages
English (en)
Other versions
MX2011008759A (es
Inventor
Pfeil Michael
Friedrich Josef
V Taylor Harold
Eisele Karl-Heinz
Brünn Cornelia
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2011008759A publication Critical patent/MX2011008759A/es
Publication of MX340772B publication Critical patent/MX340772B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo el cual enlaza específicamente a polipéptido de neurotoxina no procesado y/o parcialmente procesado o un anticuerpo el cual enlaza específicamente un epítopo el cual consiste de un péptido el cual tiene una secuencia de aminoácidos como se muestra en cualquiera de las SEQ ID NO: 1 a 16 y a métodos para la fabricación de los anticuerpos. Por otra parte, la presente invención se relaciona a una composición la cual comprende el polipéptido de neurotoxina procesado libre de polipéptido de neurotoxina no procesado o parcialmente procesado y a un método para fabricar el polipéptido de neurotoxina en base a los anticuerpos de la invención. La presente invención también se relaciona al uso del anticuerpo mencionado anteriormente para separar polipéptido de neurotoxina procesados a partir de polipéptidos de neurotoxina no procesados o parcialmente procesados o para determinar los polipéptidos de neurotoxina no procesados o parcialmente procesados. La presente invención se relaciona a un método para la fabricación de un medicamento.
MX2011008759A 2009-02-19 2010-02-17 Medios y metodos para fabricar neurotoxina altamente pura. MX340772B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20798909P 2009-02-19 2009-02-19
EP09153226 2009-02-19
US27517309P 2009-08-26 2009-08-26
EP09168679 2009-08-26
PCT/EP2010/000985 WO2010094463A1 (en) 2009-02-19 2010-02-17 Means and methods for manufacturing highly pure neurotoxin

Publications (2)

Publication Number Publication Date
MX2011008759A MX2011008759A (es) 2011-09-09
MX340772B true MX340772B (es) 2016-07-26

Family

ID=42084499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008759A MX340772B (es) 2009-02-19 2010-02-17 Medios y metodos para fabricar neurotoxina altamente pura.

Country Status (12)

Country Link
US (2) US9447175B2 (es)
EP (1) EP2398824B1 (es)
JP (1) JP5795539B2 (es)
KR (1) KR101806567B1 (es)
CN (1) CN102325792B (es)
AU (1) AU2010214834B2 (es)
BR (1) BRPI1008885B1 (es)
CA (1) CA2751311C (es)
IL (1) IL214372A0 (es)
MX (1) MX340772B (es)
RU (1) RU2571212C2 (es)
WO (1) WO2010094463A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100852821B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
ES2647243T3 (es) * 2009-04-27 2017-12-20 Merz Pharma Gmbh & Co. Kgaa Medios y métodos para la determinación de la cantidad de polipéptido Neurotoxina y de sus actividades catalíticas y proteolíticas
US8841080B2 (en) * 2009-10-21 2014-09-23 Merz Pharma Gmbh & Co. Kgaa System for determining unprocessed and partially processed neurotoxin type A
KR102083371B1 (ko) 2012-11-21 2020-03-04 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
WO2014113249A2 (en) * 2013-01-16 2014-07-24 Kci Licensing, Inc. Ion exchange enhanced absorbent systems
EP3154572A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487610B1 (en) 1989-08-16 2000-02-09 Chiron Corporation Prohormone cleavage site blocking antibody
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US6678651B2 (en) 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
DE60130266D1 (de) * 2000-11-06 2007-10-11 Us Army Med Res Mat Command Rekombinante leichte kette des botolinum neurotoxins and fusionsproteine davon zur verwendung in forschung und klinischer therapie
CA2492883C (en) * 2002-08-01 2012-10-02 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US20080171347A1 (en) * 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
KR100852821B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
US8137991B2 (en) 2006-07-24 2012-03-20 The Cleveland Clinic Foundation Methods of reducing angiogenesis of age-related macular degeneration (AMD) or choroidal neovascularization by an anti-carboxyetheylpyrrole (CFP) antibody
JP2008113592A (ja) * 2006-11-02 2008-05-22 Biseibutsu Kagaku Kenkyusho:Kk クロストリジウム・パーフリンゲンスの産生する新規な毒素
EP2048156A1 (en) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
JP2010529000A (ja) * 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌス毒素の神経毒成分をベースにした温度に安定な筋弛緩薬の提供方法
US7732579B2 (en) * 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins

Also Published As

Publication number Publication date
AU2010214834A1 (en) 2011-08-18
BRPI1008885A2 (pt) 2016-03-15
RU2571212C2 (ru) 2015-12-20
KR20110122852A (ko) 2011-11-11
IL214372A0 (en) 2011-09-27
US20120004179A1 (en) 2012-01-05
JP2012518018A (ja) 2012-08-09
MX2011008759A (es) 2011-09-09
KR101806567B1 (ko) 2018-01-10
US20160340417A1 (en) 2016-11-24
CA2751311C (en) 2019-08-06
CN102325792B (zh) 2018-01-09
AU2010214834B2 (en) 2016-04-14
US9447175B2 (en) 2016-09-20
BRPI1008885B1 (pt) 2021-09-28
EP2398824B1 (en) 2018-12-26
JP5795539B2 (ja) 2015-10-14
EP2398824A1 (en) 2011-12-28
WO2010094463A1 (en) 2010-08-26
US9963502B2 (en) 2018-05-08
CA2751311A1 (en) 2010-08-26
CN102325792A (zh) 2012-01-18
RU2011138060A (ru) 2013-03-27

Similar Documents

Publication Publication Date Title
MX340772B (es) Medios y metodos para fabricar neurotoxina altamente pura.
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
EA200700136A1 (ru) Анти-cd154-антитела
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013059885A3 (en) Polypeptide constructs and uses thereof
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
EP2403871A4 (en) SPECIFIC ANTIBODIES AND EPITOPES OF A PRION PROTEIN
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
WO2011063235A3 (en) Peptides, devices, and methods for the detection of ehrlichia antibodies
WO2012051498A3 (en) Antibodies that bind amyloid oligomers
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
IN2013MN00513A (es)
IN2012DN02869A (es)
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
ATE466876T1 (de) Immunogene konstrukte
CA2868057C (en) Epsilon toxin epitopes from clostridium perfringens with reduced toxicity

Legal Events

Date Code Title Description
FG Grant or registration